Prophylactic effect of pilocarpine on acute sialadenitis following radioactive iodine therapy in thyroid cancer patients

Choi, Eun Kyoung; Oh, Jin Kyoung; Chung, Yong-An; Jeong, Hyeonseok; Choi, Hoon; Jo, Kwanhoon

doi:10.7150/ijms.84590



Theranostics

International Journal of Biological Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Med Sci 2024; 21(3):492-495. doi:10.7150/ijms.84590 This issue Cite

Research Paper

Prophylactic effect of pilocarpine on acute sialadenitis following radioactive iodine therapy in thyroid cancer patients

Eun Kyoung Choi, M.D., Ph.D.¹, Jin Kyoung Oh, M.D., Ph.D.^1✉, Yong-An Chung, M.D., Ph.D.¹, Hyeonseok Jeong, Ph.D.¹, Hoon Choi, M.D.², Kwanhoon Jo, M.D.³

1. Department of Radiology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
2. Department of Surgery, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
3. Division of Endocrinology & Metabolism, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Citation:

Choi EK, Oh JK, Chung YA, Jeong H, Choi H, Jo K. Prophylactic effect of pilocarpine on acute sialadenitis following radioactive iodine therapy in thyroid cancer patients. Int J Med Sci 2024; 21(3):492-495. doi:10.7150/ijms.84590. https://www.medsci.org/v21p0492.htm

Other styles

Abstract

Purpose: Our aim was to evaluate the effect of prophylactic pilocarpine on acute salivary symptoms after radioactive iodine (RAI) therapy in patients with differentiated thyroid cancer.

Methods: We enrolled 88 patients (76 women and 12 men; mean age: 47 years; range: 20-74 years) with differentiated thyroid cancer who received RAI. Patients were divided into pilocarpine (51 patients) and control (37 patients) groups. Pilocarpine was given orally, at a dose of 5 mg three times a day, from 2 days before and 12 days after RAI therapy. Symptoms and signs of acute sialadenitis within 3 months of RAI therapy were recorded.

Results: During the 3 months after RAI therapy, 13 of the 88 patients (14.7%) developed acute symptomatic sialadenitis (swelling or pain of salivary glands). Acute salivary symptoms were reported by 4 (7.8%) and 9 (24.3%) patients in the pilocarpine and control groups, respectively. Acute salivary symptoms were less frequent in the pilocarpine than control group (p = 0.04), but did not differ by age, sex, or RAI dose (p = 0.3357, p = 0.428, and p = 0.2792).

Conclusions: Pilocarpine reduced the likelihood of acute sialadenitis after RAI therapy in patients with differentiated thyroid cancer.

Keywords: Thyroid Neoplasms, Pilocarpine, Sialadenitis, Pre-Exposure Prophylaxis, Radioactive Iodine

Citation styles

APA

Choi, E.K., Oh, J.K., Chung, Y.A., Jeong, H., Choi, H., Jo, K. (2024). Prophylactic effect of pilocarpine on acute sialadenitis following radioactive iodine therapy in thyroid cancer patients. International Journal of Medical Sciences, 21(3), 492-495. https://doi.org/10.7150/ijms.84590.

ACS

Choi, E.K.; Oh, J.K.; Chung, Y.A.; Jeong, H.; Choi, H.; Jo, K. Prophylactic effect of pilocarpine on acute sialadenitis following radioactive iodine therapy in thyroid cancer patients. Int. J. Med. Sci. 2024, 21 (3), 492-495. DOI: 10.7150/ijms.84590.

NLM

CSE

Choi EK, Oh JK, Chung YA, Jeong H, Choi H, Jo K. 2024. Prophylactic effect of pilocarpine on acute sialadenitis following radioactive iodine therapy in thyroid cancer patients. Int J Med Sci. 21(3):492-495.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.